Table 1 : Radiotherapy and Chemotherapy for Primary Intraocular Lymphoma.


Author Therapy Eyes Treated Primary Endpoint Median Overall
Survival
Response Rate Relapse Rate Median
Relapse
Median Follow-up

Margolis et al.,[44] WBRT 13 Remission Duration 12 months 69% 22% 7.5 months 24 months
Hoffman et al.,[46] WBRT;
IV/IT CHOP, EPOCH, and/or MTX
18 Survival 16 months - 79% 14.5 months -
Mikami et al.,[17] EBRT 22 3-Year Survival 89% at 36 months 95% 55% 28 months 36 months
Hormigo et al.,[4] EBRT; WBRT;
IV MTX, VCR, PCB, CHOP and/or Ara-C
17 Survival 39 months 82% 79% 16.5 months -
Isobe et al.,[15] EBRT; PCI;
IV HD-MTX, MTX, or CHOP
15 Survival 41 months 87% - - -
Sandor et al.,[50] IV HD-MTX, TTP, VCR, DXS;
IT Ara-C, MTX
14 Survival 68.8% at 54 months 79% 36% - -
Batchelor et al.,[52] HD-MTX 9 Remission Duration - 44% 43% 17 months -
Smith et al.,[56] IVT MTX; IV cyclophosphamide, procarbazine,
MTX, VP-16, or Ara-C
26 Safety, Response Rate 62.5% at 18.5 months 100% - - 18.5 months
Frenkel et al.,[8] IVT MTX 44 Safety, Response Rate - 100% 48% 17 months 16.2 months

WBRT, whole brain radiation therapy; IV, intravenous; IT, intrathecal; CHOP, cyclophosphamide, doxorubicin, vincristine and prednisone; EPOCH, etoposide, doxorubicin, vincristine, cyclophosphamide, and prednisone; MTX, methotrexate; VCR, vincristine; PCB, procarbazine; Ara-C, cytarabine; EBRT, external beam radiation therapy; PCI, prophylactic cranial irradiation; HD-MTX, high dose methotrexate; TTP, thiotepa; DXS, dexamethasone; IVT, intravitreal; VP-16, etoposide.

Alexandru et al.Journal of Cancer Therapeutics and Research  2013 2:15DOI : 10.7243/2049-7962-2-15